melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
|
23569304 |
2013 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
|
23614898 |
2013 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
|
23414587 |
2013 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor.
|
23076151 |
2012 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor.
|
23076151 |
2012 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
|
22761467 |
2012 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
|
22761467 |
2012 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
|
20179705 |
2010 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
|
20179705 |
2010 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
|
20130576 |
2010 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
|
20130576 |
2010 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Recurring mutations found by sequencing an acute myeloid leukemia genome.
|
19657110 |
2009 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Recurring mutations found by sequencing an acute myeloid leukemia genome.
|
19657110 |
2009 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
|
18390968 |
2008 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
|
18390968 |
2008 |
Non-Small Cell Lung Carcinoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
Somatic mutations affect key pathways in lung adenocarcinoma.
|
18948947 |
2008 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
Distinct sets of genetic alterations in melanoma.
|
16291983 |
2005 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
Distinct sets of genetic alterations in melanoma.
|
16291983 |
2005 |
Non-Small Cell Lung Carcinoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
BRAF and RAS mutations in human lung cancer and melanoma.
|
12460918 |
2002 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
Ras mutations in human melanoma: a marker of malignant progression.
|
8120410 |
1994 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
Ras mutations in human melanoma: a marker of malignant progression.
|
8120410 |
1994 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
N-ras mutations in human cutaneous melanoma from sun-exposed body sites.
|
2674680 |
1989 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
N-ras mutations in human cutaneous melanoma from sun-exposed body sites.
|
2674680 |
1989 |
Stage IV Cutaneous Melanoma AJCC v6 and v7
|
|
0.010 |
GeneticVariation
|
BEFREE |
Subsequently, we quantified ctDNA ((V600E)BRAF,(V600K)BRAF or (Q61H)NRAS) in 6 stage IV melanoma patients across several time points during their treatment course.
|
26095797 |
2015 |
Stage IV Skin Melanoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Subsequently, we quantified ctDNA ((V600E)BRAF,(V600K)BRAF or (Q61H)NRAS) in 6 stage IV melanoma patients across several time points during their treatment course.
|
26095797 |
2015 |